Oxbow Advisors LLC cut its position in shares of Sanofi (NYSE:SNY) by 2.2% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 79,940 shares of the company’s stock after selling 1,795 shares during the period. Oxbow Advisors LLC’s holdings in Sanofi were worth $3,830,000 as of its most recent SEC filing.
A number of other hedge funds have also made changes to their positions in the company. Russell Investments Group Ltd. acquired a new stake in shares of Sanofi during the fourth quarter worth about $1,606,000. Guggenheim Capital LLC increased its stake in shares of Sanofi by 1.5% in the fourth quarter. Guggenheim Capital LLC now owns 21,558 shares of the company’s stock worth $872,000 after buying an additional 311 shares during the period. Migdal Insurance & Financial Holdings Ltd. acquired a new stake in shares of Sanofi during the fourth quarter worth about $483,000. Philadelphia Trust Co. increased its stake in shares of Sanofi by 7.6% in the fourth quarter. Philadelphia Trust Co. now owns 49,300 shares of the company’s stock worth $1,994,000 after buying an additional 3,500 shares during the period. Finally, Beacon Financial Group increased its stake in shares of Sanofi by 0.9% in the first quarter. Beacon Financial Group now owns 79,526 shares of the company’s stock worth $3,566,000 after buying an additional 725 shares during the period. 9.96% of the stock is owned by institutional investors.
Sanofi (NYSE SNY) opened at 47.55 on Friday. The company has a 50-day moving average price of $47.99 and a 200 day moving average price of $46.11. The firm has a market cap of $119.42 billion, a PE ratio of 11.23 and a beta of 0.88. Sanofi has a 12 month low of $36.81 and a 12 month high of $50.24.
Sanofi (NYSE:SNY) last issued its earnings results on Monday, July 31st. The company reported $0.74 earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of $0.74. Sanofi had a net margin of 25.89% and a return on equity of 25.34%. The firm had revenue of $8.66 billion for the quarter, compared to analysts’ expectations of $8.71 billion. The company’s quarterly revenue was down 2.3% compared to the same quarter last year. Equities research analysts anticipate that Sanofi will post $3.26 EPS for the current year.
WARNING: This piece of content was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright legislation. The correct version of this piece of content can be read at https://www.com-unik.info/2017/08/12/oxbow-advisors-llc-has-3-83-million-stake-in-sanofi-sny-updated-updated.html.
A number of analysts have issued reports on SNY shares. Zacks Investment Research downgraded Sanofi from a “buy” rating to a “hold” rating in a report on Tuesday, April 25th. BidaskClub raised Sanofi from a “hold” rating to a “buy” rating in a report on Friday, June 23rd. J P Morgan Chase & Co reaffirmed a “neutral” rating on shares of Sanofi in a report on Thursday, April 20th. Cowen and Company reaffirmed a “market perform” rating and set a $52.00 price target (up from $46.00) on shares of Sanofi in a report on Tuesday, August 1st. Finally, Berenberg Bank downgraded Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, May 11th. Two analysts have rated the stock with a sell rating, nine have given a hold rating and five have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $63.75.
Sanofi Company Profile
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
What are top analysts saying about Sanofi? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Sanofi and related companies.